Biosenta Inc. has signed a milestone Memorandum of Understanding dated October 5, 2022, with VORAN GROUP VENTURES Ltd. ("Voran") which will lead the way for the commercialization of Biosenta's Tri-Filler® antimicrobial products in Canadian markets and worldwide. The patented new material science Tri-Filler® products could set the new standard in antimicrobial materials as a safe and proactive option against biological and ecological threats.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4 CAD | 0.00% |
|
0.00% | +81.82% |
1st Jan change | Capi. | |
---|---|---|
+81.82% | 9.27M | |
+15.20% | 26.63B | |
-4.17% | 16.86B | |
-15.30% | 7.05B | |
+6.63% | 5.99B | |
-7.31% | 3.03B | |
-2.22% | 2.24B | |
-7.12% | 1.93B | |
+21.87% | 917M | |
+4.27% | 667M |
- Stock Market
- Equities
- ZRO Stock
- News Biosenta Inc.
- Biosenta Inc. Enters into an MOU with Voran Group Ventures Ltd. to Collaborate on the Commercialization of Biosenta's Tri-Filler® Products